- Home
- ACV vs CRDF Comparison
ACV vs CRDF Comparison
Compare ACV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACV
- CRDF
- Stock Information
- Founded
- ACV 2015
- CRDF 1999
- Country
- ACV United States
- CRDF United States
- Employees
- ACV N/A
- CRDF N/A
- Industry
- ACV Finance/Investors Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACV Finance
- CRDF Health Care
- Exchange
- ACV Nasdaq
- CRDF Nasdaq
- Market Cap
- ACV 234.1M
- CRDF 144.4M
- IPO Year
- ACV N/A
- CRDF N/A
- Fundamental
- Price
- ACV $23.47
- CRDF $2.17
- Analyst Decision
- ACV
- CRDF Strong Buy
- Analyst Count
- ACV 0
- CRDF 5
- Target Price
- ACV N/A
- CRDF $11.10
- AVG Volume (30 Days)
- ACV 38.8K
- CRDF 1.2M
- Earning Date
- ACV 01-01-0001
- CRDF 11-06-2025
- Dividend Yield
- ACV 9.20%
- CRDF N/A
- EPS Growth
- ACV N/A
- CRDF N/A
- EPS
- ACV N/A
- CRDF N/A
- Revenue
- ACV N/A
- CRDF $545,000.00
- Revenue This Year
- ACV N/A
- CRDF N/A
- Revenue Next Year
- ACV N/A
- CRDF N/A
- P/E Ratio
- ACV N/A
- CRDF N/A
- Revenue Growth
- ACV N/A
- CRDF N/A
- 52 Week Low
- ACV $16.82
- CRDF $1.90
- 52 Week High
- ACV $23.74
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ACV 69.25
- CRDF 38.40
- Support Level
- ACV $22.95
- CRDF $1.90
- Resistance Level
- ACV $23.20
- CRDF $2.39
- Average True Range (ATR)
- ACV 0.26
- CRDF 0.13
- MACD
- ACV 0.07
- CRDF 0.03
- Stochastic Oscillator
- ACV 100.00
- CRDF 40.91
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.